Today's headline articles

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.

Today's journal articles

WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking BMP/SMAD/ID1 signaling.

Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.

Synthesis, biological evaluation, and structure - activity relationship study of novel cytotoxic aza - caffeic acid derivatives.

Development of methotrexate proline prodrug to overcome resistance by MDA - MB - 231 cells.

Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Single Dose Study With 4SC-203 in Healthy Volunteers

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Previous Journal Entries

VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.

Synthesis and biological evaluation of anilino substituted pyrimidine linked pyrrolobenzodiazepines as potential anticancer agents.

Proline isosteres in a series of 2,4 - disubstituted pyrrolo[1,2 - f][1,2,4]triazine inhibitors of IGF - 1R kinase and IR kinase.

1-(3',4',5'-trimethoxyphenyl)-3-(3'',4''-dimethoxy-2''-hydroxyphenyl)-propane with microtubule-depolymerizing ability induces G2/M phase arrest and apoptosis in HepG2 cells.

H(2)O(2) preferentially synergizes with nitroprusside to induce apoptosis associated with superoxide dismutase dysregulation in human melanoma irrespective of p53 status: antagonism by o-phenanthroline.

Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas.

Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.

Structure - Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor.

Discovery of imidazo[1,2 - b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit - to - lead study and structure - activity relationship.

Diminished Sensitivity of Chronic Lymphocytic Leukemia cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood.

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105.

Design and synthesis of heterobimetallic topoisomerase I and II inhibitor complexes: In vitro DNA binding, interaction with 5' - GMP and 5' - TMP and cleavage studies.

Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.

The Accuracy of (18)[F]-Fluoro-2-Deoxy-D: -Glucose-Positron Emission Tomography/Computed Tomography, Ultrasonography, and Enhanced Computed Tomography Alone in the Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma.

18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.

Discovery of imidazo[1,2 - a]pyrazine - based Aurora kinase inhibitors.

New synthetic flavone derivatives induce apoptosis of hepatocarcinoma cells.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer.

Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study.

Today's News Items

Eisai Announces Extension of FDA Review of Drug Application for Investigational Agent Eribulin Mesylate

Training Courses & Meetings

No events listed

Previous News Items

Eisai Announces Extension of FDA Review of Drug Application for Investigational Agent Eribulin Mesylate

---

For faster discovery, automatically organize PubMed results into categories